M. Amdahl

发表

The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics

H. Parving, G. Remuzzi, D. de Zeeuw, 2009, American Journal of Nephrology.

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.

D. Batlle, S. Sprague, F. Llach, 2003, Kidney international.

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study

D. Goldsmith, S. Marx, M. Ketteler, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

PARICALCITOL COMPARED TO CINACALCET WITH LOW-DOSE VITAMIN D THERAPY FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HAEMODIALYSIS: RESULTS OF THE IMPACT SHPT RESEARCH

D. Goldsmith, A. Sharma, S. Khan, 2013 .

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study

M. Wolf, D. Goldsmith, S. Marx, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Clinical safety and performance of VIVIA: a novel home hemodialysis system

Angelito A. Bernardo, P. McFarlane, J. Leypoldt, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Vasopressin release is enhanced by the Hemocontrol biofeedback system and could contribute to better haemodynamic stability during haemodialysis

M. Wolf, D. Goldsmith, S. Marx, 2013 .

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

S. Goldstein, J. Melnick, L. Williams, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Differential Effects of Paricalcitol and Calcitriol on Intestinal Calcium Absorption in Hemodialysis Patients

R. Heaney, L. Williams, D. Andress, 2009, American Journal of Nephrology.

Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.

K. Martin, F. Llach, J. Lindberg, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.

A. Mathes, S. Marx, J. Melnick, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

H. Parving, G. Remuzzi, E. Ritz, 2010, The Lancet.

Performance of hemodialysis with novel medium cut-off dialyzers

C. Wanner, D. Krieter, L. Nilsson, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study

D. de Zeeuw, E. Ritz, D. Coyne, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.

N. Chen, Xueqing Yu, J. Qian, 2014, Clinical nephrology.